Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.
BACKGROUND
Human papilloma virus (HPV) prevalence studies performed in different regions and population groups across Canada would inform public health decisions regarding implementation of anti-HPV vaccines.


METHODS
A total of 8,700 liquid-based specimens from 8,660 women aged 13-86 from throughout British Columbia were collected. DNA was isolated from 4,980 of these samples and assessed for HPV prevalence and type distribution. HPV was detected by PCR analysis using tagged GP5+/6+ consensus primers to amplify the L1 region of HPV; typing was done by bi-directional sequencing of PCR products.


RESULTS
Overall HPV prevalence was 16.8% (age adjusted 15.5%). Prevalence of high-risk HPV was 13.9, and 10.7% of samples contained HPV16. HPV prevalence was highest in the youngest group of women (<20 years). One-third of HPV positive samples contained more than one HPV type. Percentages of low-grade (LGIL) and high-grade intraepithelial lesions (HGIL) containing high-risk HPV are 52.3 and 79.4%, respectively.


CONCLUSIONS
Overall HPV prevalence in this study is within the range of estimates from other studies. The prevalence of HPV16 is higher than what is found in other Canadian and international studies. HPV16 and HPV18 compose a majority of the high-risk virus in this study. Use of current HPV vaccines could considerably reduce HPV-related conditions including cervical cancer and procedures such as colposcopy.
Moore
Richard A
RA
Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, 675 West 10th Ave., Vancouver, BC, V5Z 1L3, Canada.
Ogilvie
Gina
G
Fornika
Daniel
D
Moravan
Veronika
V
Brisson
Marc
M
Amirabbasi-Beik
Mahsa
M
Kollar
Anita
A
Burgess
Thomas
T
Hsu
Ray
R
Towers
Laura
L
Lo
Jane
J
Matisic
Jasenka
J
Brooks-Wilson
Angela
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001955:British Columbia / Q000453:epidemiology; D004279:DNA, Viral / Q000032:analysis; D003710:Demography; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology; D052161:Human papillomavirus 18 / Q000235:genetics / Q000276:immunology; D006801:Humans; D032541:Mass Vaccination / Q000379:methods* / Q000706:statistics & numerical data; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use; D015995:Prevalence; D012703:Serotyping; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D014626:Vaginal Smears / Q000706:statistics & numerical data; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology
D004279:DNA, Viral; D053918:Papillomavirus Vaccines